19 September 2019 : Meta-Analysis
Association of RAGE rs1800625 Polymorphism and Cancer Risk: A Meta-Analysis of 18 Case-Control Studies
Yuzhong Xu1CF, Zhenhua Lu23BF, Na Shen4D, Xiong Wang4AE*DOI: 10.12659/MSM.916260
Med Sci Monit 2019; 25:7026-7034
Abstract
BACKGROUND: Accumulating evidence suggests that the rs1800625 polymorphism in RAGE promoter region might be associated with cancer risk; however, data from different studies show conflicting results. Here, a meta-analysis was conducted to evaluate the associations between RAGE rs1800625 polymorphism and cancer risk.
MATERIAL AND METHODS: We searched Embase (Excerpt Medica Database), PubMed, and CNKI (Chinese National Knowledge Infrastructure) databases until March 15, 2019 to identify potential studies for the meta-analysis.
RESULTS: Eighteen eligible studies were included in the current meta-analysis, representing 6246 cases and 6819 controls. Pooled analysis showed positive correlation between the RAGE rs1800625 polymorphism and susceptibility of cancer in recessive genetic model [CC versus TC+TT: odds ratio (OR)=1.397, 95% confidence interval (CI): 1.031–1.894, P=0.031]. Subgroup analysis revealed this association in the Asian, but not Caucasian population, and this correlation was not detected in either breast or lung cancer. Sensitivity analysis indicated unstable results, which should be interpreted with caution. No publication bias was observed.
CONCLUSIONS: In conclusion, the RAGE rs1800625 polymorphism was associated with increased overall cancer risk in Asians in recessive genetic model. However, large-scale and well-designed studies in different populations and diverse cancer types are needed for a precise conclusion.
Keywords: Disease Susceptibility, Polymorphism, Genetic, Case-Control Studies, Gene Frequency, Genetic Association Studies, Genetic Predisposition to Disease, Mitogen-Activated Protein Kinases, Neoplasms, Polymorphism, Single Nucleotide, Publication Bias, Risk Factors
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952